住友制药：人iPSC来源垂体-下丘脑类器官移植在垂体功能减退小鼠及食蟹猴模型中恢复激素分泌

Functional analysis of adrenocorticotropic-hormone–producing pituitary cells derived from human pluripotent stem cells in murine and primate models of hypopituitarism

AI 导读

住友制药宣布，RACTHERA、名古屋大学研究生院等报告将人多能干细胞（hPSC）来源的垂体-下丘脑类器官移植至皮下组织，在垂体功能减退小鼠和食蟹猴模型中恢复了激素分泌。该研究为全球首次在非人灵长类模型中证明垂体-下丘脑类器官移植有效。

正文

Print（PDF/407KB） Oct. 02, 2026 R&D

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced that RACTHERA Co., Ltd., the Nagoya University Graduate School of Medicine and others have reported that transplantation of human pluripotent stem cell (hPSC)-derived pituitary-hypothalamic organoids into subcutaneous tissue restored hormone production in animal models of hypopituitarism (mice and a cynomolgus macaque).

This represents the world's first report demonstrating the efficacy of pituitary-hypothalamic organoid transplantation in a non-human primate model. Please refer to the attached material for further details.